Biomarkers · Inflammation
Soluble CD163 (sCD163)
Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
sCD163 and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in sCD163, study by study
1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| lifestyle | Three-month lifestyle intervention programme in adults with non-alcoholic fatty liver disease | Serum sCD163 fell 0.64 mg/L (-640 ng/mL) from baseline after the 3-month lifestyle programme; n=126 | RCT | Rødgaard-Hansen S, et al. Scand J Clin Lab Invest. 2017;77(7):498-504. |
Sources
- Risk curve: Knudsen TB 2016 (PMID 27354366): all-cause HR 1.06 (1.03-1.09) per 1 mg/L increase in baseline plasma sCD163. Scaled to published population values.
- Knudsen TB, Ertner G, Petersen J, Moller HJ, Moestrup SK, Eugen-Olsen J, et al. Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals. Journal of Infectious Diseases. 2016;214(8):1198-1204.
Map Soluble CD163 (sCD163) against another biomarker.
Related markers: Alpha-1-Antichymotrypsin (AACT) · Alpha-1-Antitrypsin (AAT) · Antinuclear Antibodies (ANA) · CD4:CD8 T-Cell Ratio · CD8+ T-Cell Count · Erythrocyte Sedimentation Rate (ESR) · Fibrinogen · Growth Differentiation Factor-15 (GDF-15)